Literature DB >> 19111874

Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy.

Giulio Francia1, Urban Emmenegger, Robert S Kerbel.   

Abstract

While targeting VEGF has shown success against a number of human cancers, drug resistance has resulted in compromised clinical benefits. In this issue of Cancer Cell, Crawford et al. (2009) report that tumors resistant to anti-VEGF therapy stimulate tumor-associated fibroblasts to express proangiogenic PDGF-C, implicating it as a potential therapeutic target.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19111874     DOI： 10.1016/j.ccr.2008.12.011

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  17 in total

1.  PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets.

Authors:  Xu Hou; Anil Kumar; Chunsik Lee; Bin Wang; Pachiappan Arjunan; Lijin Dong; Arvydas Maminishkis; Zhongshu Tang; Yang Li; Fan Zhang; Shi-Zhuang Zhang; Piotr Wardega; Sagarika Chakrabarty; Baoying Liu; Zhijian Wu; Peter Colosi; Robert N Fariss; Johan Lennartsson; Robert Nussenblatt; J Silvio Gutkind; Yihai Cao; Xuri Li
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

2.  The tumor microenvironment in colorectal carcinogenesis.

Authors:  Vijay G Peddareddigari; Dingzhi Wang; Raymond N Dubois
Journal:  Cancer Microenviron       Date:  2010-03-05

Review 3.  Targeting tumor cell motility to prevent metastasis.

Authors:  Trenis D Palmer; William J Ashby; John D Lewis; Andries Zijlstra
Journal:  Adv Drug Deliv Rev       Date:  2011-06-02       Impact factor: 15.470

Review 4.  Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors.

Authors:  Nandini Dey; Pradip De; Leyland-Jones Brian
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

5.  Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins.

Authors:  Yawu Jing; Huarui Lu; Kailang Wu; Indira V Subramanian; S Ramakrishnan
Journal:  Int J Cancer       Date:  2011-04-01       Impact factor: 7.396

6.  Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.

Authors:  Mohammad H Pourgholami; Zhao Y Cai; Samina Badar; Kiran Wangoo; Marianne S Poruchynsky; David L Morris
Journal:  BMC Cancer       Date:  2010-04-15       Impact factor: 4.430

7.  VEGF-independent angiogenic pathways induced by PDGF-C.

Authors:  Xuri Li; Anil Kumar; Fan Zhang; Chunsik Lee; Yang Li; Zhongshu Tang; Pachiappan Arjuna
Journal:  Oncotarget       Date:  2010-08

8.  Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts.

Authors:  Giulio Francia; Shan Man; Chyan-Jang Lee; Christina R Lee; Ping Xu; Miriam E Mossoba; Urban Emmenegger; Jeffrey A Medin; Robert S Kerbel
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

9.  Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.

Authors:  Christina Hackl; Shan Man; Giulio Francia; Chloe Milsom; Ping Xu; Robert S Kerbel
Journal:  Gut       Date:  2012-04-28       Impact factor: 23.059

Review 10.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.

Authors:  Fanglong Wu; Jin Yang; Junjiang Liu; Ye Wang; Jingtian Mu; Qingxiang Zeng; Shuzhi Deng; Hongmei Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.